Unichem Laboratories is planning for integration and consolidation of the generics formulations business in the US market of M/s Bayshore Pharmaceuticals LLC (wholly owned subsidiary of Company’s holding company, Ipca Laboratories) into Unichem Pharmaceuticals (USA) Inc. (company’s wholly owned subsidiary) so as to consolidate all the Ipca Group’s USA generics formulations business under one entity. The meeting of the Board of Directors of the Company scheduled to be held on September 30, 2024 to consider the same.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company.
